Eric J. Hyllengren Sells 1,364 Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Stock

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) CFO Eric J. Hyllengren sold 1,364 shares of the stock in a transaction on Monday, November 18th. The shares were sold at an average price of $11.20, for a total value of $15,276.80. Following the completion of the sale, the chief financial officer now directly owns 23,392 shares of the company’s stock, valued at $261,990.40. The trade was a 5.51 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Atara Biotherapeutics Price Performance

Shares of NASDAQ ATRA opened at $10.54 on Friday. The stock has a market capitalization of $60.68 million, a PE ratio of -0.41 and a beta of 0.50. Atara Biotherapeutics, Inc. has a one year low of $6.50 and a one year high of $39.50. The business’s fifty day moving average price is $9.14 and its 200-day moving average price is $10.11.

Atara Biotherapeutics (NASDAQ:ATRA) last posted its earnings results on Tuesday, November 12th. The biotechnology company reported ($2.93) earnings per share for the quarter, topping the consensus estimate of ($3.77) by $0.84. The business had revenue of $40.19 million during the quarter, compared to analysts’ expectations of $23.00 million. During the same quarter in the previous year, the business earned ($16.50) EPS. As a group, equities analysts expect that Atara Biotherapeutics, Inc. will post -12.12 EPS for the current fiscal year.

Institutional Investors Weigh In On Atara Biotherapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Atara Biotherapeutics in the second quarter worth $53,000. Cubist Systematic Strategies LLC purchased a new stake in Atara Biotherapeutics during the 2nd quarter worth about $79,000. State Street Corp boosted its stake in Atara Biotherapeutics by 52.3% in the 3rd quarter. State Street Corp now owns 22,353 shares of the biotechnology company’s stock worth $182,000 after purchasing an additional 7,680 shares during the period. FMR LLC grew its holdings in Atara Biotherapeutics by 41.7% during the 3rd quarter. FMR LLC now owns 25,061 shares of the biotechnology company’s stock valued at $204,000 after buying an additional 7,381 shares in the last quarter. Finally, Delap Wealth Advisory LLC bought a new stake in shares of Atara Biotherapeutics during the first quarter valued at about $29,000. Institutional investors own 70.90% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on ATRA shares. Mizuho upgraded shares of Atara Biotherapeutics from a “neutral” rating to an “outperform” rating and decreased their price objective for the company from $25.00 to $18.00 in a research note on Friday, August 16th. Canaccord Genuity Group increased their price target on shares of Atara Biotherapeutics from $13.00 to $21.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. Finally, HC Wainwright reaffirmed a “neutral” rating on shares of Atara Biotherapeutics in a research report on Wednesday, August 21st. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $16.67.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.